Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from Financing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tenax Therapeutics (TENX) Depreciation and Depletion (2016 - 2024)

Tenax Therapeutics' Depreciation and Depletion history spans 7 years, with the latest figure at $2621.0 for Q4 2017.

  • On a quarterly basis, Depreciation and Depletion fell 33.68% to $2621.0 in Q4 2017 year-over-year; TTM through Dec 2017 was $12621.0, a 33.41% decrease, with the full-year FY2023 number at $7570.0, up 47.19% from a year prior.
  • Depreciation and Depletion hit $2621.0 in Q4 2017 for Tenax Therapeutics, down from $3000.0 in the prior quarter.
  • Over the last five years, Depreciation and Depletion for TENX hit a ceiling of $31224.0 in Q4 2015 and a floor of $2621.0 in Q4 2017.
  • Historically, Depreciation and Depletion has averaged $14266.1 across 5 years, with a median of $18000.0 in 2015.
  • Biggest five-year swings in Depreciation and Depletion: changed 0.0% in 2013 and later plummeted 87.34% in 2016.
  • Tracing TENX's Depreciation and Depletion over 5 years: stood at $23000.0 in 2013, then decreased by 8.7% to $21000.0 in 2014, then surged by 48.69% to $31224.0 in 2015, then plummeted by 87.34% to $3952.0 in 2016, then crashed by 33.68% to $2621.0 in 2017.
  • Business Quant data shows Depreciation and Depletion for TENX at $2621.0 in Q4 2017, $3000.0 in Q3 2017, and $3000.0 in Q2 2017.